

Title	Content	Pg. No.
	Declaration by Research Scholar–Originality of Research Work	VI
	Certificate of Supervisor	VII
	Thesis Approval Form	VIII
	Declaration by Research Scholar – Submission of Thesis	IX
	Acknowledgement	X
	Contents	II
	List of Figures	IV
	List of Tables	V
	Abstract	XII
Chapter: 1	Name of the Chapter	
	1 Introduction	13
Chapter: 2	Name of the Chapter	
	2 Literature Review	19
	2.1 Drug-Induced Liver Injury (DILI)	19
	2.2 Role of Plasma Binding, Transporters, and Mitochondrial Cytochrome P450 Enzymes in Drug-Induced Mitochondrial Toxicity	26
	2.3 Evaluating Mitotoxicity as Either a Single or Multi-Mechanistic Insult in the Context of Hepatotoxicity	26
	2.4 Mitochondrial Dysfunction in Hepatotoxicity	26
	2.5 Regulatory Perspective on Mitochondrial DILI	28
	2.6 Overview of Mitochondrial-Toxic Drugs	31
	2.7 Post-Marketing Surveillance and Risk Management	34
	2.8 Drugs Associated with Mitochondrial Hepatotoxicity	35
	2.9 Chloramphenicol and Mitochondrial Dysfunction	39
	2.10 Experimental Models for Mitochondrial DILI	41
	2.11 Translational Considerations	43
	2.12 Antioxidant Therapy for Mitochondrial Dysfunction in DILI	43
	2.13 Biomarkers for Mitochondrial DILI	47
	2.14 Regulatory and Translational Perspectives	50

Chapter: 3	Name of the Chapter	
3.	Aim And Objectives	55
3.1	Rationale of the Study	55
3.1.1	Rationale for Selecting Chloramphenicol	56
3.2	Objectives	56
Chapter: 4	Name of the Chapter	
4.	Materials And Methods	58
4.1	Study Overview	58
4.2	In-Vitro Methods	58
4.3	Detail of Mitochondrial-Related Genes Selected for the research	61
4.5	In Vivo Methods	64
4.6	Statistical Analysis	65
Chapter: 5	Name of the Chapter	
5.	Results	66
5.1	In-Vitro Results (Mitochondrial Toxicity Assessment by ATP Assay)	66
5.1.2	Assessment of Mitochondrial etiology status through Gene expression study	70
5.2	In-Vivo Results	72
Chapter: 6	Name of the Chapter	
6.	DISCUSSION	74
Chapter: 7	Name of the Chapter	
7.	CONCLUSION	81
	Bibliography	84
Appendix A	Plagiarism Report	
Appendix B	Publication	

APPENDIX A: PLAGIARISM REPORT

APPENDIX B: PUBLICATIONS

List of Figures

Figure No.	Name of the Figure	Pg. No.
Figure 1	Common Mechanistic Routes Linking Drug Exposure to Liver Damage	17
Figure 2	General mechanisms of drug delivery and their influence on mitochondrial function within target cells	21
Figure 3	Mechanistic pathway by which certain antibiotics (e.g., tetracyclines, aminoglycosides) may contribute to mitochondrial dysfunction	22
Figure 4	Metabolic pathways of Valproic Acid (VPA) and its role in liver toxicity	33
Figure 5	Schematic of antioxidant-mediated protection against chloramphenicol (CMP) induced liver injury in Wistar rats.	46
Figure 6	Graphs A–C show ATP-based cytotoxicity and Graph D compares ROS levels across treatment groups	66
Figure 7	Graphs demonstrating the fold change representing relative gene expression for selected genes using RT-qPCR in HepG2 cells.	70
Figure 8	Effect of antioxidants on GSH and NO levels	72

List of Tables

Table No.	Name of Table	Pg. No.
Table 1	Listing of drugs that received FDA black box warnings or were withdrawn from the market due to hepatotoxicity	29
Table 2	Examples of Drugs Associated with Mitochondrial Dysfunction-Mediated Hepatotoxicity	38
Table 3A	Target gene detail for gene expression study	60
Table 3B	Summary Table of Genes selected for study	60
Table 4	Sequences of primers for real-time PCR	61
Table 5	Long-term exposure of chloramphenicol	68
Table 6	Long-term exposure of chloramphenicol+ Astaxanthin	69
Table 7	Long-term exposure of chloramphenicol+ Quercetin	69
Table 8	Comparison of ROS production	70
Table 9	Observed GSH and NO levels in Rat Blood	72
Table 10	Summary of key findings	73